EGFR and central nervous system cancer: Though around 50% patients harbored the EGFRνIII deletion, and EGFR amplification was maintained at the time of recurrence [61,62], neither EGFR inhibitors nor monoclonal antibodies targeting extracellular EGFR showed a survival benefit among recurrent-glioma patients.